Concert Pharmaceuticals Named One of the "Fierce 15" Biotech Companies of 2008
June 24, 2008
Lexington, MA – Concert Pharmaceuticals, Inc. announced today that it has been named to the annual FierceBiotech “Fierce 15” list, designating it as one of the top biotechnology companies of 2008. The editors of FierceBiotech evaluated hundreds of privately-held firms based on a variety of factors including company vision, strength of technology, and competitive market position. A complete list of ‘Fierce 15’ companies is available in today’s issue of FierceBiotech and on the FierceBiotech Web site at www.fiercebiotech.com.
Concert Pharmaceuticals, Inc. is dedicated to creating new medicines through a novel scientific approach utilizing the naturally-occurring element deuterium. Concert applies its innovative platform to modify specific properties of validated drug molecules, yielding a rich pipeline of new chemical entities (NCEs). Concert leverages decades of pharmaceutical experience to create drug candidates with potential for best-in-class efficacy and safety, while greatly reducing R&D risk, time and expense. The Company has over 100 patent applications for new drug candidates addressing a broad range of therapeutic areas, including hot flashes, fibrotic diseases, pain and infectious disease. Concert expects to initiate its first clinical study in the second half of 2008. Additional information about Concert is available online at http://www.concertpharma.com.